Navigation Links
Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL
Date:6/8/2009

Overview of 11 peer review publications presented in 'Future Oncology'

SEATTLE, June 8 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) reports a summary of peer reviewed publications spanning preclinical, Phase I and Phase II clinical studies with pixantrone was reviewed in the May 2009 edition of Future Oncology (Volume 5, Issue 4) which is now available on line. The article, "Pixantrone: a promising drug in the treatment of non-Hodgkin lymphomas," was written by Drs. Barry W. Hancock and Loaie M. El-Helw of the Weston Park Hospital, Sheffield UK.

The review focuses on the impressive preclinical anti-tumor activity demonstrated in hematologic cancers over standard anthracyclines and the rational design modifications to the chemical compound believed to be responsible for enhanced DNA damage and binding to topoisomerase II enzyme, a key target for anthracycline mediated tumor death. These modifications are also hypothesized by the authors to underlie the drugs' low cardiotoxicity profile in preclinical animal studies when compared to standard anthracycline drugs.

Five phase I/II studies in which pixantrone was added to standard chemotherapy regimens for treating relapsed aggressive and indolent NHL were also reviewed in the article. Pixantrone, when added to standard multi-agent chemotherapy regimens produced encouragingly high rates of overall response (58-74%) including high rates of complete responses (37-57%). As previously reported, neutropenia was the dose limiting toxicity when used as a single agent.

"In both preclinical and early clinical studies pixantrone exhibited lower cardiac toxicity and better anti-tumor activity than that observed with alternative anthracyclines, as it is devoid of the putative cardiac toxicity generating chemical structure," said Barry W. Hancock, M.D., Professor of Medical Oncology
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
2. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
3. Pixantrone Shows Activity in a Preclinical Study of Experimental Autoimmune Myasthenia Gravis (EAMG)
4. Pixantrone to be Studied in Phase I/II Trial for Aggressive Multiple Sclerosis
5. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
6. Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
7. Cell Therapeutics Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
8. Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
9. Pixantrone Increases Progression-Free Survival by 81% Compared to Standard Chemotherapeutic Agents in Phase III Relapsed Aggressive non-Hodgkins Lymphoma Trial
10. Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
11. Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... 1, 2015 Hitachi Chemical Diagnostics, Inc. is ... launch of the ExoComplete™ 96-Well Plate Kit and ... for exosome collection to mRNA purification.  The products were ... Annual Meeting, April 23 – 26, 2015, in ... for research use only of molecular biology applications and ...
(Date:5/1/2015)... 01, 2015 Research and Markets ( ... "US ACO IT Spending Outlook 2018" report to ... of lives covered by ACO would grow at a ... the ACO IT spending has been studied on three ... and spending on services. Our research provides current market ...
(Date:5/1/2015)... May 1, 2015 Braeburn Pharmaceuticals ... current therapeutic focus beyond addiction and pain ... disorders. Braeburn has acquired an implantable, six-month ... risperidone for treatment of schizophrenia from Endo ... global rights to other potential applications of ...
Breaking Medicine Technology:New Products for Exosome Isolation to mRNA Purification 2United States ACO IT Spending Outlook 2014-2018 2Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 2Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 3Braeburn Pharmaceuticals expands pipeline to include two schizophrenia treatments 4
... Express Scripts, Inc., one of the largest pharmacy ... as its 2011 Supplier of the Year. ... This award recognizes suppliers who have a long-term ... improvement in supplier relationship management, quality, service, innovation ...
... Ikaria, Inc., a critical care company focused on ... significant needs of critically ill patients in the hospital ... CEO, Daniel Tasse, will present at the 2011 Lazard ... will be given on Tuesday, November 15, 2011 at ...
Cached Medicine Technology:Rexam Chosen as Express Scripts' Supplier of the Year 2Ikaria® to Present at 2011 Lazard Capital Markets Healthcare Conference 2
(Date:5/4/2015)... (PRWEB) May 04, 2015 For partners ... brand new lubricant -- Astroglide TTC™ (Trying to ... motility and alter pH levels, Astroglide TTC™ is specially ... , According to the Centers for Disease Control, an ... trouble getting pregnant or sustaining a pregnancy, and over ...
(Date:5/4/2015)... Peacock Alley knows we all feel ... mother was the most beautiful woman I ever saw.” ... feminine prints and textures to remind her just how ... Eloise Robe to get you there. The beautiful Monet-inspired print ... tapered waist. It is available in small/medium or large/extra large. ...
(Date:5/3/2015)... Barbara Crone has joined Women’s Excellence in ... of the men, women and families who seek her care, initially ... for families in the home. , “When the ... if I could complete their care with the delivery of their ... mentor Nurse Midwife, I knew it was time for me to ...
(Date:5/3/2015)... (PRWEB) May 03, 2015 Indiana Fiber ... Provider announces Bank Computer Services, Inc (BCS) has selected ... BCS’ President states, “The technology, service, and working relationship ... like is the local feel you get with IFN. ... managed company; IFN makes local decisions and operates as ...
(Date:5/3/2015)... (PRWEB) May 03, 2015 It is not too ... Brain Aneurysm Walk in Memory of Lissa Anne Been in ... organized this great family-friendly event to honor her loving memory. It ... inception. , Just having turned 37, Lissa suffered a ... away on August 24, 2012. This event is designed to serve ...
Breaking Medicine News(10 mins):Health News:Astroglide Announces the Birth of Its New Baby: Astroglide TTC 2Health News:Astroglide Announces the Birth of Its New Baby: Astroglide TTC 3Health News:Feminine Classics for Mother's Day Gifts from Peacock Alley 2Health News:Women's Excellence In Midwifery Welcomes Barbara Crone 2Health News:Bank Computer Services, Inc Selects Indiana Fiber Network, LLC as Fiber Transport Provider 2Health News:Bank Computer Services, Inc Selects Indiana Fiber Network, LLC as Fiber Transport Provider 3Health News:Renowned Brain Aneurysm Foundation to Benefit from Arnold, Missouri’s 3rd Annual Brain Aneurysm Walk in Memory of Lissa Anne Been 2
... in Britain are trying to investigate the reason why ... most people, but could make many others seriously ill. ... which is carried by cats, but can also be ... Toxoplasma causes the disease called toxoplasmosis, which in normal ...
... detected traces of dioxin in a U.S. beef consignment to ... U.S. officials and the American beef industry are still unconvinced ... 6.26 picograms, which is higher than Korea’s 5-picogram level. ... way: If we found 6.26 picograms of dioxin [in our ...
... cells on a new three-dimensional scaffold of tiny protein// ... than any other cell culture system. ,An ... may one day replace the ubiquitous Petri dish for ... ONE. Shuguang Zhang, associate director of MIT's Center for ...
... jail infrastructure and health facilities has revealed that 14 inmates ... 1999. These deaths are believed to have resulted from treatment ... has been reported that the jail infrastructure lacks adequate doctors, ... treatment for medical conditions ranging from hernia to heart disease. ...
... led to the death of a 27-week-old baby boy in ... undergoing treatment. ,The babies are undergoing treatment at ... to be carriers of Panton-Valentine Leukocidin (PVL) and tested positive ... confirmed that the baby died due to infection of this ...
... the past 50 years has declined, although the severity of ... to be a major public health concern, with more than ... It is the third leading cause of death behind heart ... disability, according to background information in the article. Prior estimates ...
Cached Medicine News:Health News:MIT Creates 3-D Scaffold for Growing Stem Cells 2Health News:MIT Creates 3-D Scaffold for Growing Stem Cells 3Health News:Incidence of Stroke on Decline Over Last 50 Years 2
Fine .12mm Tip With 5mm Platform; In Titanium....
Angled tip, 0.3mm triangular grasping tips; In Titanium....
... addition to any Trial ... Trial Frame provides a ... controls for quick, easy ... high-quality materials, and precision ...
... The Ultramatic Rx Master is ... years of reliable service and ... that measurably improve procedures. It ... need and want most, including ...
Medicine Products: